Bio-Gene to attend investor meetings in Hong Kong and present at the Ignite Investment Summit Singapore

Melbourne, Australia: Bio-Gene Technology Limited (ASX:BGT or 'Bio-Gene' or 'the Company'), an Australian company developing the next generation of novel insecticides derived from nature, is pleased to announce that it will be holding meetings with a range of investors in Hong Kong on Monday 20 April 2026, and at the Ignite Investment Summit Singapore, being held at the Fullerton Hotel 21-22 April 2026.

In addition, Bio-Gene is scheduled to present at the Ignite Investment Summit Singapore at 10:40am on Wednesday 22 April 2026.

A copy of the Company's latest investor presentation is attached below.

Parties interested in arranging to meet with Tim Grogan, Bio-Gene's CEO & Managing Director, should contact Omar Taheri via: omar@sparkplus.org.

Approved for release on ASX by Bio-Gene Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and demand for natural insecticides. Its unique products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across crop protection, grain storage, public health, animal health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

www.bio-gene.com.au

Investor Presentation

Developing new insecticides derived from nature to achieve high impact worldwide.

20 April 2026



Important Notice & Disclaimer

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company's announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitution a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. no representation, warranty or guarantee, express or implied, is given that any Forward-Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward-Looking Statements are based are reasonable.

No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.

Investment Highlights

Focused development of two new insecticides with strong commercial validation.

01. Two New Actives

Two insecticidal compounds **derived from nature with novel modes of action:**

- **Flavocide®** and **Qcide®** are derived from a unique sub-type of eucalypt
- Effective against some major insect pests with resistance to standard products
- Strong drivers are increased demand for **safer and more environmentally friendly** products

02. Large Target Markets

Crop Protection (incl. Grain Storage), **Public Health, Consumer, Animal Health,** total addressable markets of $44B, as **both stand-alone** and **combination** products[1]

03. Focused Pipeline

Pipeline of eight product opportunities:

- Public Health – control of vectors of disease
- Crop Protection, Professional Turf and Ornamentals
- Grain Storage Protection
- Consumer (Home & Garden)
- Animal Health

04. Strong Partnering Progress

Three partnerships to date:

- Clarke Mosquito (US), Evergreen Garden Care (EU, UK, AU & NZ), STK (global) & collaboration with Envu, Sumitomo Corporation & Nakashima Trading (in progress)

1. Sources: Precedence Research (2025); Europe Insecticides Market (Market Data Forecast) 2025, MarketsandMarkets vector control market (2024), Grand View Research pest control products market (2024); U.S. pest control products (2025); Japan pest control products (2025), IMARC household insecticides market (2024); Inkwood Japan home insecticides market (2021), IMARC stored grain insecticides market (2025), Grand View Research flea, tick and heartworm products market (2024). 2. Qcide® and Flavocide® are registered trademarks of Bio-Gene Technology Limited.

The Global Challenges We Help Solve

Our products address the demand for effective pest control & sustainable agriculture.

The mosquito is "the world's deadliest animal"[1]

- Causes more human deaths than any other creature on earth
- 247 million malaria cases in 2021, in 84 malaria endemic countries[2]
- Between 2019 - 20 malaria deaths increased by 10% to 625,000[3]
- Over 32,000 cases of Dengue recorded in Singapore in 2022[4]

Pesticides are critical to farming

- 20-40% of global food production lost to pests - est. US$2 trillion per year[5] and increasing spread of pests due to:
  - growing insect resistance to current insecticides
  - climate change
  - increased population pressures
- The estimated annual losses for the six major Australian grain crops due to invertebrate pests is est. A$360M[6]
- CropLife's US survey found that 72% of respondents "*are planning to increase the number of biological products their companies sell to grower-customers during the coming year*"

1. US Centers for Disease Control and Prevention, 2. Global expansion and redistribution of Aedes-borne virus transmission risk with climate change, SJ. Ryan et. Al, 3. World Malaria Report 2022, 4. NEA Launches National Dengue Prevention Campaign Early To Urge Continued Vigilance And Avert A Dengue Outbreak In 2023, 5. Savary, S., Willocquet, L., Pethybridge, S.J. et al. The global burden of pathogens and pests on major food crops., 6. Nat Ecol Evol 3, 430–439 (2019), 7. 'The current and potential costs of invertebrate pests in grain crops', GRDC, 8. 2024 CropLife magazine Biologicals online survey, The state of US crop biologicals in 2024 (agfundernews.com)

The (Big) Problem of Resistance

- Pests continue to develop resistance to almost all insecticides with >16,500 individual cases across 339 insecticide types in 2019[1].
- Between 20% to 40% of global crop production is lost to pests annually.
- Each year, invasive insects cost the global economy approx. $290 billion. (FAO)



1. Sparks et al 2020, Insecticides, biologics and nematicides: Updates to IRAC's mode of action classification - a tool for resistance management. Pesticide Biochemistry and Physiology 167

Our Unique Products Derived from Nature

01

Qcide®

Qcide is an 100% natural oil extracted from the leaves of a specific cultivar of eucalypt (*Gypmie messmate*) currently farmed in northern Australia. OMRI Listed (US)

- ✓ *15th harvest in QLD completed in early 2026*

02

Flavocide®

Flavocide is based on flavesone, a naturally occurring plant compound synthesised via a proprietary process that allows production in large volumes for global demand.

- ✓ *Pilot-scale production completed at Rallis India Ltd*

Patent families owned by Bio-Gene include: (1) Control of resistant pests.(2) Use in synergistic combinations, (3) Control of specific pests e.g., aphids, (4) Ovicidal activity against insect pests e.g., mites, bed bugs. Territories: Australia & New Zealand, USA/Europe, Latin America (Brazil), Japan, China, Africa (RSA)

Illustrative Efficacy Data - Flavocide®

Flavocide direct (spray chamber) and residue (surface spray) summary data

Mosquito	Test	Material	Rate	KD50 (secs)	KD90 (secs)	KD100 (secs)	24hr Mortality (%)
Aedes aegypti	Direct spray*	Flavesone	50mg/ml	488	633		100
Aedes aegypti	Direct spray*	Flavesone	25mg/ml	570	788		100
Culex quinquefasciatus	Direct spray*	Flavesone	50mg/ml	1025.1	1431		100
Culex quinquefasciatus	Direct spray*	Flavesone	25mg/ml	1606	1932		100
Aedes aegypti	Residual tile	Flavesone	50mg/ml	-	-	900	100
Aedes aegypti	Residual tile	Flavesone	20mg/ml	-	-	900	100
Culex quinquefasciatus	Residual tile	Flavesone	50mg/ml	-	-	900	100
Culex quinquefasciatus	Residual tile	Flavesone	20mg/ml	-	-	1800	100

Flavocide space & surface sprays provided rapid knockdown and 100% mortality at 24h.

For a range of Flavocide-related data also see: 1. Gregory Daglish, R. Jagadeesan, P. Burrill, M. Nayak (DAFF), P. May, A. Wade (Bio-Gene) (2024) Potential of flavesone as a grain protectant: Long-term efficacy and residues for controlling the lesser grain borer, Rhyzopertha dominica (F.), in stored wheat. Journal of Stored Products Research 109 (2024) 102467, 2. Peter May (Bio-Gene) (2021) Natural β-triketone insecticides with novel mode of action for mosquito control. 14th Mosquito Control Association of Australia Symposium – presentation, 3. Dr Sue Knights (2020) Native plants a novel ally. GRDC Ground Cover Supplement – Interebrate Pest Management: New Frontiers Issue 149 Nov-Dec 2020 p16, 4. Peter Miller & Bryce Peters (UTS) (2017) Flavocide: A novel insecticide for the control of urban pests. Proceedings of the Ninth International Conference on Urban Pests (ICUP) – paper, 5. Maria V. Murgia, Phurchhoki Sherpa, Catherine A. Hill (2025) Assessment of New, Natural Product Formulation to Control Ticks in Midwest, United States, 17th Lyme Borreliosis International Conference, Chicago, presentation

Illustrative Efficacy Data - Qcide®

Household pests – ants & cockroaches

Argentine Ant

Red Imported Fire Ant

German Cockroach





For a range of Qcide-related data also see e: 1. Peter Miller, Bryce Peters (UTS) & Peter May (Bio-Gene) (2022) Qcide: Natural insecticide for the control of flying insects. Proceedings of the Tenth International Conference on Urban Pests (ICUP) – poster, 2. Peter May (2016) New β-triketone insecticides offer novel mode of action to control resistant insects. International Pest Control Nov-Dec pp310-311

Flavocide® Development – Studies & First Regulatory Application Timeline*

The regulatory-enabling studies are now well advanced.



** This estimate is subject to a range of factors, including continued availability of planned study slots scheduled with CROs and achievement of planned study start dates, QA release, data review, study report finalization and availability of capital required for completion of these studies and other business operations.*

Bio-Gene's Business Model and the Insecticide Supply Chain

Bio-Gene licenses its technology and supplies the active ingredient (Flavocide or Qcide).



Bio-Gene will typically generate a commercial return via:

1. Royalties based on a % of the Manufacturer's Net Sales, and
2. Margin on the supply of Flavocide or Qcide

Calculation of the royalty based on a % of the Manufacturer's Net Sales:

- Size of the relevant market (territory/market segment)
- Market share achieved at the customer level
- Net Sales by manufacturer and downstream gross margins for the supply chain
- BGT license royalty rate (%)

Note: The diagram is representative and may vary by territory and product. Some functions overlap, are merged or not required, depending on the target market

Size of the Global Insecticide Market

Bio-Gene is targeting all four market segments with key partners

1st priority market segment for Flavocide, with earliest market entry.

Bio-Gene's regulatory strategy is to file first in Australia, leverage in other regional territories and to file in other major markets (e.g. US), with some accelerated pathways to market.

Segment (Est. 2024, US$B)[1]	Worldwide	%	Australia	USA	Japan	EU	ROW
Public health vector control & Professional pest management	6.9 B	15.7%	100 M	1.4 B	200 M	1.2 B	4.1 B
Consumer insect control	7.8 B	17.6%	100 M	1.2 B	1 B	1.4 B	4.2 B
Agricultural & stored grain insecticides/acaricides	21.6 B	49.0%	700 M	4.7 B	400 M	5.6 B	10 B
Animal health	7.9 B	17.7%	200 M	2.3 B	300 M	2.4 B	2.7 B
Total:	**44.2 B**	**100.0%**	**1.1 B**	**9.6 B**	**1.9 B**	**10.6 B**	**21 B**

clarke (Flavocide)

envu (Flavocide)

- The worldwide insecticide is expected to grow by ~5–7% CAGR to US$60-65 billion through to 2030[3]
- Bio-Gene's strategy is to pursue the earliest path to market and to leverage the strengths of both Flavocide and Qcide into multiple applications

1. Some segment territory sizes estimates are based on direct published values, while others are indicative allocations. 2. Sources: Precedence Research (2025); Europe Insecticides Market (Market Data Forecast) 2025, MarketsandMarkets vector control market (2024), Grand View Research pest control products market (2024); U.S. pest control products (2025); Japan pest control products (2025), IMARC household insecticides market (2024); Inkwood Japan home insecticides market (2021), IMARC stored grain insecticides market (2025), Grand View Research flea, tick and heartworm products market (2024). 3. Grand View Research (2025), Ken Research (2025), Precedence Research (2025)

Size of the Global Insecticide Market

Bio-Gene is targeting all four market segments with key partners

Flavocide and Qcide are positioned for use by consumers, inc. home & garden and household nuisance insect pests (Japan).

Bio-Gene plans to leverage initial regulatory data into applications in agriculture and horticulture, requiring additional information (e.g. e-fate, MRLs, etc).

Bio-Gene has recently entered into a commercial evaluation of Flavocide in animal health.

Segment (Est. 2024, US$B)	Worldwide	%	Australia	USA	Japan	EU	ROW
Public health vector control & Professional pest management	6.9 B	15.7%	100 M	1.4 B	200 M	1.2 B	4.1 B
Consumer insect control	7.8 B	17.6%	100 M	1.2 B	1 B	1.4 B	4.2 B
Agricultural & stored grain insecticides/acaricides	21.6 B	49.0%	700 M	4.7 B	400 M	5.6 B	10 B
Animal health	7.9 B	17.7%	200 M	2.3 B	300 M	2.4 B	2.7 B
Total:	**44.2 B**	**100.0%**	**1.1 B**	**9.6 B**	**1.9 B**	**10.6 B**	**21 B**

(Flavocide & Qcide)

(Qcide)

(Flavocide)

(Qcide)

(Funding support Flavocide)

1. Some segment territory sizes estimates are based on direct published values, while others are indicative allocations. 2. Sources: Precedence Research (2025); Europe Insecticides Market (Market Data Forecast) 2025, MarketsandMarkets vector control market (2024), Grand View Research pest control products market (2024); U.S. pest control products (2025); Japan pest control products (2025), IMARC household insecticides market (2024); Inkwood Japan home insecticides market (2021), IMARC stored grain insecticides market (2025), Grand View Research flea, tick and heartworm products market (2024).

2025 – Bio-Gene Awarded U.S. Department of Defense Grants Totalling A$3.0m

Deployed Warfighter Protection (DWFP) program - new product opportunities in defense

The DWFP program is a U.S. Department of Defense program administered by the U.S. Armed Forces Pest Management Board that supports development of novel technologies to protect U.S. military personnel from threats posed by disease-carrying insect pests.

Flavocide® in a wearable emanator device

- A wearable product containing Flavocide to control mosquitoes and other insect vectors of disease (Dengue, Malaria, etc)
- Controlled Release Device developed by GearJump Technologies
- A$1.6M (US$972,449) over three years, (A$64,000 to BGT)
- Collaborators:
  - U.S. Army Combat Capabilities Development Command, Maryland
  - Center for Medical, Agricultural and Veterinary Entomology, Agricultural Research Service, Florida
  - Walter Reed Army Institute of Research, Bangkok

Qcide® to provide residual control of bed bugs & crawling insects

- A sprayable formulation of Qcide® to provide residual control of bed bug infestations, flies and other crawling insects
- A$1.4M (US$892,492) over three years, (A$159,000 to BGT)
- Collaborators:
  - Walter Reed Army Institute of Research, Maryland,
  - Center for Medical, Agricultural and Veterinary Entomology, Florida

These grants are a strong validation of Bio-Gene's technology and will enable development of two innovative products containing Flavocide® and Qcide® for commercialisation in both the military and civilian markets.

Recent Milestones & News flow

14 November 2025

Qcide® – OMRI organic listing in the US

ASX ANNOUNCEMENT
14 November 2025

BIO-GENE TECHNOLOGY LTD

Qcide® receives organic listing status in USA

Highlights

- The Organic Materials Review Institute (OMRI) based in the USA has evaluated Qcide® for compliance with the USDA National Organic Program (USDA NOP)
- Qcide has been approved by OMRI for listing as a Botanical Pesticide under the USDA NOP in the OMRI Products List
- Strengthens Bio-Gene's commercial positioning of Qcide for future use in a range of applications including in organic and sustainable pest control markets
- Qcide is a natural, non-synthetic essential oil produced and being developed by Bio-Gene as a novel insecticide, derived from *Eucalyptus cloeziana* and extracted by steam distillation

OMRI LISTED

3 March 2026

Flavocide® regulatory development

ASX ANNOUNCEMENT
3 March 2026

BIO-GENE TECHNOLOGY LTD

Progress in regulatory development of Flavocide® and first regulatory submission timeline

Highlights

- Flavocide® development program and toxicology studies are progressing well
- Results from initial toxicology studies have supported progression into the major reproductive and neurotoxicity studies
- Bio-Gene is targeting submission of its first application for registration of Flavocide as a new active constituent with APVMA in March 2027[1]
- The first application will seek approval of Flavocide active constituent to initially support product registrations as an insecticide for professional and domestic use
- Studies are generating data to OECD standards and will support subsequent regulatory submissions in other target countries[2]

16 March 2026

Qcide® to be launched in Japan

ASX ANNOUNCEMENT
16 March 2026

BIO-GENE TECHNOLOGY LTD

Bio-Gene, Sumitomo Corporation and Nakashima Trading Co. to launch Qcide® in Japan for use against household nuisance insects

Highlights

- Major Japanese trading and manufacturing companies Sumitomo Corporation and Nakashima Trading Co. to develop and market a range of insecticide products containing Bio-Gene's 100% natural Qcide®
- Targeting Japan's household nuisance insect pest market – expected launch late 2026
- Term sheet signed and definitive agreements expected by late April/early May 2026
- Bio-Gene to supply Qcide oil produced in Queensland
- Sumitomo Corporation to coordinate the ordering, trade financing, transportation, and import approval for the supply of Qcide
- Nakashima Trading Co. to undertake formulation, packaging, promotion and supply of product range to retail outlets
- The home insecticide market in Japan is currently estimated at US$1B in sales annually

Key Forward Milestones & News Flow

Bio-Gene has many catalysts to drive value over the next 18 months, with a strong pipeline of near-term news flow.

Strategic priorities:	(1) Speed	(2) Focused product development	(3) Commercial validation	(4) Efficient use of capital

01

Flavocide & Qcide development

- ✓ Results of Flavocide regulatory studies (multiple)
- ✓ Submission of Flavocide regulatory dossier in Australia
- ✓ Qcide faster to market & regulatory development milestones
- ✓ Qcide scale-up and harvest/processing progress

02

Partnering & commercial

- ✓ New commercial partnerships & collaborations
  - Vector control
  - Consumer uses
  - Agriculture
  - Animal health
- ✓ Expansion of current licenses
- ✓ Receipt of milestone payments
- ✓ Patents granted

03

Funding & other support

- ✓ Grant funding successes
- ✓ Synergistic program/product opportunities
- ✓ International funding support & validation

Global Agriculture Biological Sector – Major Licensing/Collaboration Deals

Multinational companies seeking all-round collaborations to maximize resources & portfolio offerings

	Licensee	Licensors	Activity	Uses	Timing
Multinational companies	syngenta	• Biotalys • Provivi • Lavie Bio	• Joint development of biosolutions • Eco granules & dispenser • New biological insecticides	• Crop Protection • Fall Armyworm & Yellow Stem Borer • Crop Protection	• April 2023 • September 2024 • February 2024
	BAYER	• AlphaBioControl	• Biological insecticide	• Oilseed rape & cereals	• April 2024
	BASF	• Agrospheres	• Biological insecticide	• Lepitoteran pests	• October 2024
	CORTEVA agriscience	• Bioceres	• Distribution	• Seed application	• July 2023
	UPL OpenAg	• AgBiTech • Biome Makers	• Distribution • Tech devel	• Crop Protection • Soil health	• February 2023 • May 2023
	FMC	• Novozymes	• Enzyme based biocontrols	• Crop & Prof Pests	• Feb 2021
	Sumitomo	• Futureco Bioscience	• Product development & manufacturing	• Sustainable ag	• March 2025
	SUMITOMO CHEMICAL	• Ginkgo Bioworks	• Product development & manufacturing	• Multiple Ag uses	• July 2023

Global Agriculture Biological Sector – Major Acquisition Deals

The biologicals category has seen a large number of acquisitions – to position for the future

Year	Acquiring Company	Target Company	Major components
2026	BASF	- AgBiTech	• Biological insect control
2024 & 2025	sas	- Agroquimica - Aquo do Brazil - Prevesa Agroscience	• Key biological crop protection products
2025	EURAZEO	- Bioline Agrosciences	• Microbials
2024 & 2025	Sumitomo	- DPH Biologicals - Insumos Nativa - Futureco Bioscience SA	• Crop Protection products • Crop Protection • Biological nutrition & protection products • Biological products
2025	Bioline AgroSciences	- Kenogard	• Crop protection products
2025	syngenta	- Novartis Natural Compounds - Intrinsyx Bio	• Biological crop protection
2023	UPL OpenAg	- Ceratis	• Novel tech platforms
2023	Rovensa Next	- Agro K - Cosmosel - Acro	• Key Biological Crop Protection & Nutrition Products

Experienced Board of Directors & Management Team

A team with strong experience in product development, partnering and commercialisation.

Alex Ding
Chairman

Previously partner at two law firms and expert in M&A, capital markets, and general corporate law.

Andrew Guthrie
Non-Executive Director

32 years' experience in agriculture globally, formerly a member of Syngenta's leadership team.

Tim Grogan
MD & CEO

30 years' experience growing companies in the agtech, food and human health sectors.

Drew Speedy
CFO & Company Secretary

20 years' experience as CFO across both listed and unlisted companies.

Chris Ramsey
Non-Executive Director

Over 30 years' experience in agriculture business start up, development, marketing & agronomy.

Peter May
Executive Director R&D

Over 30 years' experience in crop protection market.

Dr James Wade
Program Manager

PhD with 10+ years experience in research in a broad range of agricultural verticals.

Richard Jagger
Commercial Advisor (Business Development)

25+ years in agriculture.

Capital Structure

Key metrics (16 April 2026)

ASX code	BGT
Share price	$0.035
Market Capitalisation	~A$10.7m
Shares on issue	305,061,108
Options on issue[(a)]	110,070,192
Cash (31 Dec 2025)	A$1.08m

(a) Options balance includes:
- 55,035,096 options with an exercise price of $0.034 and expiry of 15-05-2028
- 55,035,096 options with an exercise price of $0.046 and expiry of 15-05-2030

Contact

Tim Grogan
Managing Director & CEO
bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
matt@nwrcommunications.com.au
0451 896 420

Omar Taheri
Spark Plus
omar@sparkplus.org

Bio-Gene Technology Limited (ABN 32 071 735 950)